Top

Published in:

01-06-2022 | Migraine | Original Article

Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data

Authors: Simona Guerzoni, Carlo Baraldi, Umberto Pensato, Valentina Favoni, Flavia Lo Castro, Maria Michela Cainazzo, Sabina Cevoli, Luca Pani

Published in: Neurological Sciences | Issue 6/2022

Abstract

Background

Erenumab is a monoclonal antibody acting against calcitonin gene-related peptide receptor which has been found effective even for the treatment of chronic migraine (CM) complicated with medication overuse headache (MOH). According to the present guidelines, the treatment with erenumab should continue for up to 1 year. The aim of the present study is to explore the evolution of patients affected by CM and MOH at the baseline, after erenumab discontinuation.

Methods

One hundred and eighty-five patients affected by CM and MOH were recruited and followed up after erenumab discontinuation. The number of migraine days per month, the number of painkillers taken per month, the number of days in which one medication was used for a month were collected every 30 days for the 3 months following erenumab suspension.

Results

At the 3rd month after suspension, patients displayed a significantly higher number of migraine days per month, a significantly higher painkiller consumption, and a significantly higher migraine-related disability. A high body mass index and the presence of aura were positively correlated with the relapse of CM and MOH.

Conclusion

Patients affected by CM and MOH at the baseline displayed a significant worsening of their headaches after erenumab discontinuation.

Ashina M (2020) Migraine. N Eng J Med 383:1866–1876. https://doi.org/10.1056/NEJMra1915327CrossRef

Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38:1–211. https://doi.org/10.1177/0333102417738202CrossRef

Diener HC, Holle D, Solbach K, Gaul C (2016) Medication-overuse headache: risk factors, pathophysiology and management. Nat Rev Neurol 12:575–583. https://doi.org/10.1038/nrneurol.2016.124CrossRefPubMed

GBD (2016) Disease and Injury Incidence and Prevalence Collaborators (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390:1211–1259. https://doi.org/10.1016/S0140-6736(17)32154-2CrossRef

Chiang CC, Schwedt TJ, Wang SJ, Dodick DW (2016) Treatment of medication-overuse headache: a systematic review. Cephalalgia 36:371–381. https://doi.org/10.1177/0333102415593088CrossRefPubMed

Sun-Edelstein C, Rapoport AM, Rattanawong W, Srikiatkhachorn A (2021) The evolution of medication overuse headache: history, pathophysiology and clinical update. CNS Drugs 35:545–565. https://doi.org/10.1007/s40263-021-00818-9CrossRefPubMed

Cainazzo MM, Baraldi C, Ferrari A, Lo Castro F, Pani L, Guerzoni S (2021) Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study. Neurol Sci 42:4193–4202. https://doi.org/10.1007/s10072-021-05105-5CrossRefPubMed

Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD, Martelletti P (2019) European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain 20:6. https://doi.org/10.1186/s10194-018-0955-yCrossRefPubMedPubMedCentral

De Matteis E, Affaitati G, Frattale I, Caponnetto V, Pistoia F, Giamberardino MA, Sacco S, Ornello R (2021) Early outcomes of migraine after erenumab discontinuation: data from a real-life setting. Neurol Sci 42:3297–3303. https://doi.org/10.1007/s10072-020-05022-zCrossRefPubMed

10.

Gantenbein AR, Agosti R, Gobbi C, Flugel D, Schenkin CJ, Viceic D, Zecca C, Pohl H (2021) Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment - a real-life cohort study. Cephalalgia 41:1181–1186. https://doi.org/10.1177/03331024211014616CrossRefPubMedPubMedCentral

11.

Raffaelli B, Terhart M, Overeem LH, Mecklenburg J, Neeb L, Steinicke M, Reuter U (2021) Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study. Cephalalgia; 3331024211046617. https://doi.org/10.1177/03331024211046617.

12.

Yang M, Rendas-Baum R, Varon SF, Kosinski M (2011) Validation of the Headache Impact Test (HIT-6^TM) across episodic and chronic migraine. Cephalalgia 31:357–367. https://doi.org/10.1177/0333102410379890CrossRefPubMedPubMedCentral

13.

D’Amico D, Mosconi P, Genco S, Usai S, Prudenzano AMP, Grazzi L, Leone M, Puca FM, Bussone G (2001) The migraine disability assessment (MIDAS) questionnaire: translation and reliability of the Italian version. Cephalalgia 10:947–952. https://doi.org/10.1046/j.0333-1024.2001.00277.xCrossRef

14.

Raffaelli B, Mussetto V, Israel H, Neeb L, Reuter U (2019) Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination. J Headache Pain 20:66. https://doi.org/10.1186/s10194-019-1018-8CrossRefPubMedPubMedCentral

15.

DeMatteis E, Guglielmetti M, Ornello R, Spuntarelli V, Martelletti P, Sacco S (2020) Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives. Expert Rev Neurother 20:627–641. https://doi.org/10.1080/14737175.2020.1772758CrossRef

16.

Lee MJ, Lee SY, Cho S, Kang ES, Chung CS (2018) Feasibility of serum CGRP measurement as a biomarker of chronic migraine: a critical reappraisal. J Headache Pain 19:53. https://doi.org/10.1186/s10194-018-0883-xCrossRefPubMedPubMedCentral

17.

Greco R, De Icco R, Demartini C, Zanaboni AM, Tumelero E, Sances G, Allena M, Tassorelli C (2020) Plasma levels of CGRP and espression of specific microRNAs in blood cells of episodic and chronic migraine subjects: towards the identification of a panel of peripheral biomarkers of migraine? J Headache Pain 21:122. https://doi.org/10.1186/s10194-020-01189-0CrossRefPubMedPubMedCentral

18.

Tringali G, Vollono C, Calabresi P, Navarra P (2020) A proof-of-concept study on CGRP plasma levels of migraineurs during a 6-month treatment with ERENUMAB. J Headache Pain 21:124. https://doi.org/10.1186/s10194-020-01193-4CrossRefPubMedPubMedCentral

19.

Bigal ME, Lipton RB (2011) Migraine chronification. Curr Neur Neurosci Rep 11:139–148. https://doi.org/10.1007/s11910-010-0175-6CrossRef

20.

Marics B, Peitl B, Varga A, Pàzmàndi K, Bàcsi A, Németh J, Szilvàssy Z, Jancsò G, Dux M (2017) Diet-induced obesity alters dural CGRP release and potentiates TRPA1-mediated trigeminovascular responses. Cephalalgia 37:581–591. https://doi.org/10.1177/0333102416654883CrossRefPubMed

21.

Vernieri F, Altamura C, Brunelli N, Maria Costa C, Aurilia C, Egeo G, Fofi L, Favoni V, Pierangeli G, Lovati C, Aguggia C, d’Onofrio F, Doretti A, Di Fiore P, Finocchi C, Rao R, Bono F, Ranieri A, Albanese M, Cevoli S, Barbanti P, GARLIT Study Group (2021) Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). J Headache Pain 22:35. https://doi.org/10.1186/s10194-021-01247-1CrossRef

22.

Alpuente A, Gallardo VJ, Torres-Ferrùs M, Alavrez-Sabin J, Pozo-Rosich P (2020) Short and mid-term predictors of response to OnabotulinmtoxinA: real-life experience observational study. Headache 60:677–685CrossRef

23.

Tozzi A, De Iure A, Di Filippo M, Costa C, Caproni S, Pisani A, Bonsi P, Picconi B, Cupini LM, Materazzi S, Geppetti P, Sarchielli P, Calabresi P (2012) Critical role of calcitonin gene-related peptide receptors in cortical spreading depression. Proc Natl Acad Sci 109:18985–18990CrossRef

24.

Close LN, Eftekhari S, Wang M, Charles AC, Russo AF (2019) Cortical spreading depression as a site of origin for migraine: role of CGRP. Cephalalgia 39:428–434CrossRef

25.

Baraldi C, Ornello R, Favoni V, Sacco S, Caponnetto V, Pierangeli G, Pani L, Cevoli S, Guerzoni S (2021) Chronic migraine and medication overuse headache worsening after OnabotulinumtoxinA withdrawn due to the severe acute respiratory syndrome-coronavirus-2 pandemic. Front Neurol 12:647995CrossRef

Title: Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data
Authors: Simona Guerzoni
Carlo Baraldi
Umberto Pensato
Valentina Favoni
Flavia Lo Castro
Maria Michela Cainazzo
Sabina Cevoli
Luca Pani
Publication date: 01-06-2022
Publisher: Springer International Publishing
Keywords: Migraine
Analgesics in Dentistry
Medication Overuse Headache
Aura
Headache
Erenumab
Published in: Neurological Sciences / Issue 6/2022
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-022-05870-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2022

Scrub typhus presenting as diaphragmatic myoclonus

An invisible cause of disability: stigma in migraine and epilepsy

Safety and efficacy of intravenous thrombolysis in patients with acute stroke and active cancer: retrospective cohort study

Telemedicine application to headache: a critical review

Are COVID-19 vaccines safe for people with epilepsy? A cross-sectional study

Questionnaire-based survey on the prevalence of medication-overuse headache in Japanese one city—Itoigawa study